LAPORTE KATHLEEN 4

What Happened Kathleen LaPorte, a director of Q32 Bio Inc. (QTTB), received a derivative award on June 12, 2026 covering 9,810 shares. The reported acquisition price is $0.00 (award/option style), so the Form 4 shows $0 intrinsic value at grant. The award is a compensatory grant rather than an open-market purchase or sale.

Key Details

• Transaction date: June 12, 2026; Form filed June 16, 2026 (timely — within two business days of the transaction).
• Transaction type: A (award/grant of a derivative security) — 9,810 shares reported at $0.00.
• Shares owned after transaction: not disclosed in this filing.
• Vesting note (from filing): the shares underlying the option vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to the reporting person’s continued service.
• No indication in the filing that shares were immediately sold or that a 10b5‑1 or tax‑withholding event applied.

Context This is a standard equity compensation award to a director. Because it is a derivative/award that vests in the future, it does not represent an immediate purchase or sale of stock and does not by itself indicate buying/selling sentiment. Retail investors may watch for future exercise or sales, or for changes in the insider’s reported total holdings, to assess any subsequent insider activity.